Company news

Rhythm Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Rhythm Pharmaceuticals Enters into a Non-dilutive Revenue Interest Financing Agreement with HealthCare Royalty for up to $100 Million

June 15, 2022

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Use in Patients with Bardet-Biedl Syndrome

June 15, 2022

Rhythm Pharmaceuticals Presents New Data from Long-term Extension Trial Evaluating Setmelanotide in Bardet-Biedl Syndrome or POMC or LEPR Deficiency Obesity at ENDO 2022

June 12, 2022

Rhythm Pharmaceuticals Presents Initial Data from Long-term Extension Trial Evaluating Setmelanotide in Rare Genetic Diseases of Obesity at ENDO 2022

June 12, 2022

Rhythm Pharmaceuticals to Present at BofA Securities 2022 Healthcare Conference

May 3, 2022

Rhythm Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Update

May 2, 2022

Rhythm Pharmaceuticals Presents New Data from Phase 3 Trial Evaluating Setmelanotide in Patients with Bardet-Biedl Syndrome (BBS) at the Pediatric Endocrine Society (PES) 2022 Virtual Annual Meeting

May 1, 2022

Rhythm Pharmaceuticals to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022

April 25, 2022

Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity

April 5, 2022

Rhythm Pharmaceuticals to Present at Cowen & Co. 42nd Annual Health Care Conference

February 28, 2022

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

February 28, 2022

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome

February 23, 2022

Rhythm Pharmaceuticals Announces Promotions within its Executive Leadership Team

February 22, 2022

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 1, 2022

February 21, 2022

Rhythm Pharmaceuticals Announces Positive Interim Data from Long-term Extension Study of Setmelanotide in Bardet-Biedl Syndrome (BBS)

February 15, 2022

Rhythm Pharmaceuticals to Host Virtual Bardet-Biedl Syndrome (BBS) Event on February 16

February 7, 2022

Rhythm Pharmaceuticals Announces First Patients Dosed in DAYBREAK and Weekly Trials Evaluating Setmelanotide for Rare Genetic Diseases of Obesity

January 12, 2022

Rhythm Pharmaceuticals and RareStone Ltd. Announce Exclusive Licensing Agreement for the Development and Commercialization of IMCIVREE (setmelanotide) in China

December 5, 2021

Rhythm Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome

November 14, 2021

Rhythm Pharmaceuticals to Present at Stifel 2021 Virtual Healthcare Conference

November 8, 2021

Rhythm Pharmaceuticals Reports Third Quarter 2021 Financial Results

November 1, 2021

Rhythm Pharmaceuticals Presents First-ever Data Showing Improvements in Health-related Quality of Life for Patients Living with Bardet-Biedl Syndrome at ObesityWeek® 2021

October 31, 2021

Rhythm Pharmaceuticals to Report Third Quarter 2021 Financial Results on Tuesday, November 2, 2021

October 19, 2021

Rhythm Pharmaceuticals Presents New Data on Experience of People Living with Rare Genetic Diseases of Obesity and Provides Updates on Uncovering Rare Obesity® Genetic Testing Program

October 13, 2021

Rhythm Pharmaceuticals Completes Submission of Type II Variation Application to the European Medicines Agency for IMCIVREE® (setmelanotide) for Bardet-Biedl and Alström Syndromes

October 13, 2021

Rhythm Pharmaceuticals Presents New Data from Phase 2 and 3 Trials Evaluating Setmelanotide in Multiple Rare Genetic Diseases of Obesity at the 59th Annual ESPE Meeting

September 21, 2021

Rhythm Pharmaceuticals Announces Marketing Authorisation of IMCIVREE® (setmelanotide) in Great Britain

September 20, 2021

CORRECTION: Rhythm Pharmaceuticals, Inc.

September 20, 2021

Rhythm Pharmaceuticals Completes Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for IMCIVREE® (setmelanotide) for the treatment of obesity and control of hunger in Bardet-Biedl and Alström Syndromes

September 19, 2021

Rhythm Pharmaceuticals Announces Expanded Access Program for Setmelanotide for Patients with Bardet-Biedl Syndrome

September 7, 2021

Rhythm Pharmaceuticals to Present at Morgan Stanley 19th Annual Global Healthcare Conference

September 1, 2021

Rhythm Pharmaceuticals Announces CMO Transition

September 1, 2021

Rhythm Pharmaceuticals to Present at the 59th Annual ESPE Meeting

August 11, 2021

Rhythm Pharmaceuticals to Present at 2021 Canaccord Genuity 41st Annual Growth Conference

August 4, 2021

Rhythm Pharmaceuticals Reports Second Quarter 2021 Financial Results

August 2, 2021

Rhythm Pharmaceuticals Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseases of Obesity

August 2, 2021

Rhythm Pharmaceuticals Announces Senior Leadership Additions

July 28, 2021

Rhythm Pharmaceuticals Announces Collaborative Research Agreement with Clinical Registry Investigating Bardet-Biedl Syndrome

July 27, 2021

Rhythm Pharmaceuticals to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021

July 26, 2021

Rhythm Pharmaceuticals Announces European Commission Authorization of IMCIVREE® (setmelanotide)▼ for the Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency

July 22, 2021

Rhythm Pharmaceuticals and Medison Pharma Partner to Commercialize IMCIVREE™ (setmelanotide) in Israel

July 21, 2021

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency

May 20, 2021

Rhythm Pharmaceuticals Reports First Quarter 2021 Financial Results

May 2, 2021

Rhythm Pharmaceuticals Announces Late-Breaking Data Presentations at ENDO 2021

March 8, 2021

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

February 28, 2021

Rhythm Pharmaceuticals, Inc. Announces Closing of $172.5 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

February 9, 2021

Rhythm Pharmaceuticals Announces Positive Data with Setmelanotide in Additional MC4R Pathway Deficiency-related Obesities

January 25, 2021

Rhythm Pharmaceuticals Announces Sale of Priority Review Voucher for $100M

January 4, 2021

Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes

December 21, 2020

Rhythm Pharmaceuticals Announces Appointments of Camille L. Bedrosian, M.D., and Lynn Tetrault, J.D., to its Board of Directors

December 10, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 58 decks. Every deck is listed under its year.